Forma Therapeutics, Inc.

This study tests a daily pill called etavopivat in 27 children (ages 12-16) with sickle cell disease who are at higher risk for a first stroke. The medicine aims to improve blood flow in the brain and reduce stroke risk. Participants take the pill for one year, with an option to …

This study tests a once-daily pill called etavopivat in children aged 6 months to 18 years with sickle cell disease. The main goals are to check the medicine's safety and how it moves through the body. Participants take the pill every day for 96 weeks and have regular check-ups. …